Diabetic Foot Ulcers - Pipeline Review, H1 2018 - ResearchAndMarkets.com

June 5, 2018

DUBLIN--(BUSINESS WIRE)--Jun 5, 2018--The “Diabetic Foot Ulcers - Pipeline Review, H1 2018” report has been added to ResearchAndMarkets.com’s offering.

Diabetic Foot Ulcers - Pipeline Review, H1 2018, provides an overview of the Diabetic Foot Ulcers (Metabolic Disorders) pipeline landscape.

Diabetic Foot Ulcers - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Diabetic Foot Ulcers (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diabetic Foot Ulcers (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Foot Ulcers and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 13, 9, 2, 15, 3 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Diabetic Foot Ulcers (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered:

Introduction Diabetic Foot Ulcers - Overview Diabetic Foot Ulcers - Therapeutics Development Diabetic Foot Ulcers - Therapeutics Assessment Diabetic Foot Ulcers - Companies Involved in Therapeutics Development Diabetic Foot Ulcers - Drug Profiles Diabetic Foot Ulcers - Dormant Projects Diabetic Foot Ulcers - Discontinued Products Diabetic Foot Ulcers - Product Development Milestones Appendix

Companies Mentioned

ANP Technologies Inc Boston Therapeutics Inc CardioVascular BioTherapeutics Inc Chrysalis BioTherapeutics Inc CytoTools AG Energenesis Biomedical Co Ltd EyeGene Inc FirstString Research Inc Genentech Inc GlaxoSmithKline Plc Human Stem Cells Institute Izun Pharmaceuticals Corp Lakewood-Amedex Inc MallInckrodt Plc MediWound Ltd NovaLead Pharma Pvt Ltd OliX Pharmaceuticals Inc Oneness Biotech Co Ltd Pherecydes Pharma SA ProMetic Life Sciences Inc Serodus ASA Stempeutics Research Pvt Ltd TechnoPhage SA Topadur Pharma AG USV Pvt Ltd ViroMed Co Ltd

For more information about this report visit https://www.researchandmarkets.com/research/b55f45/diabetic_foot?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180605006736/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Endocrine and Metabolic Disorders Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 06/05/2018 05:09 PM/DISC: 06/05/2018 05:09 PM


Update hourly